Uncovering the Fundamentals of EXAS – A Deep Dive into Exact Sciences

By Tamara Parker • Wednesday, February 07 15:39 • Permanent Link

Exact Sciences marked a -4.6% change today, compared to 1.0% for the S&P 500. Is it a good value at today's price of $61.63? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Exact Sciences belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
The company's P/B ratio is 3.57
Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -39.0 based on its trailing 12 month price to earnings (EPS) of $-1.58 per share
Its forward P/E ratio is -62.3, based on its forward earnings per share (EPS) of $-0.99
EXAS has a Price to Earnings Growth (PEG) ratio of -0.47, which shows the company has a fair value when we factor growth into the price to earnings calculus.
Over the last four years, Exact Sciences has averaged free cash flows of $-188583000.0, which on average grew 37.7%
Exact Sciences has moved -4.7% over the last year compared to 20.3% for the S&P 500 -- a difference of -25.1%
EXAS has an average analyst rating of buy and is -32.69% away from its mean target price of $91.56 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.